retatrutide for type 2 diabetes Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people A New Obesity Drug Delivered

J Cell Biol 217:22732289

(2018) 360:j5145

For those intrigued by dual-action treatments, Zepbound with tirzepatide offers further increased efficacy, up to 20.9% body weight loss, by concurrently targeting GLP-1 and GIP receptors

Retatrutides triple mechanism of action: The science behind it The combined activation of these three receptors promotes weight loss and metabolic control more efficiently than other medications

A separate analysis published in the journal Addiction examined real-world pharmacy data and found that GLP-1 prescriptions correlated with decreased fills of naltrexone and other AUD medications, suggesting that patients may have been experiencing reduced drinking independently

Important Timeline Disclaimer: These timelines are general patterns and may not reflect individual experiences